PMID- 31493625
OWN - NLM
STAT- MEDLINE
DCOM- 20200512
LR  - 20200518
IS  - 1532-2238 (Electronic)
IS  - 1096-6374 (Linking)
VI  - 48-49
DP  - 2019 Oct-Dec
TI  - The insulin-like growth factor-I receptor stimulating activity (IRSA) in health 
      and disease.
PG  - 16-28
LID - S1096-6374(19)30038-3 [pii]
LID - 10.1016/j.ghir.2019.08.001 [doi]
AB  - Determination of true IGF-I bioactivity in serum and other biological fluids is 
      still a substantial challenge. The IGF-IR Kinase Receptor Activation assay 
      (IGF-IR KIRA assay) is a novel tool to asses IGF-IR stimulating activity (IRSA) 
      and has opened a new era in studying the IGF system. In this paper we discuss 
      many studies showing that measuring IRSA by the IGF-IR KIRA assay often provides 
      fundamentally different information about the IGF system than the commonly used 
      total IGF-I immunoassays. With the IGF-IR KIRA assay phosphorylation of tyrosine 
      residues of the IGF-IR is used as read out to quantify IRSA in unknown (serum) 
      samples. The IGF-IR KIRA assay gives information about net overall effects of 
      circulating IGF-I, IGF-II, IGFBPs and IGFBP-proteases on IGF-IR activation and 
      seems especially superior to immunoreactive total IGF-I in monitoring therapeutic 
      interventions. Although the IRSA as measured by the IGF-IR KIRA assay probably 
      more closely reflects true bioactive IGF-I than measurements of total IGF-I in 
      serum, the IGF-IR KIRA assay in its current form does not give information about 
      all the post-receptor intracellular events mediated by the IGF-IR. Interestingly, 
      in several conditions in health and disease IRSA measured by the IGF-IR KIRA 
      assay is considerably higher in interstitial fluid and ascites than in serum. 
      This suggests that both the paracrine (local) and endocrine (circulating) IRSA 
      should be measured to get a complete picture about the role of the IGF system in 
      health and disease.
CI  - Copyright (c) 2019 Elsevier Ltd. All rights reserved.
FAU - Janssen, Joseph A M J L
AU  - Janssen JAMJL
AD  - Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 
      Rotterdam, the Netherlands. Electronic address: j.a.m.j.l.janssen@erasmusmc.nl.
FAU - Varewijck, Aimee J
AU  - Varewijck AJ
AD  - Department of Internal Medicine, Division of Endocrinology, Erasmus MC, 
      Rotterdam, the Netherlands.
FAU - Brugts, Michael P
AU  - Brugts MP
AD  - Department of Internal Medicine, Ikazia Hospital, Rotterdam, the Netherlands.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190821
PL  - Scotland
TA  - Growth Horm IGF Res
JT  - Growth hormone & IGF research : official journal of the Growth Hormone Research 
      Society and the International IGF Research Society
JID - 9814320
RN  - 0 (IGF1 protein, human)
RN  - 67763-96-6 (Insulin-Like Growth Factor I)
RN  - EC 2.7.10.1 (Receptor, IGF Type 1)
SB  - IM
MH  - Disease/*etiology
MH  - Humans
MH  - Insulin-Like Growth Factor I/*metabolism
MH  - Receptor, IGF Type 1/*metabolism
MH  - Signal Transduction
OTO - NOTNLM
OT  - Disease
OT  - Endocrine
OT  - Health
OT  - IGF-I
OT  - IGF-I bioactivity
OT  - IGF-I receptor
OT  - Immunoassays
OT  - KIRA
OT  - Paracrine
EDAT- 2019/09/08 06:00
MHDA- 2020/05/19 06:00
CRDT- 2019/09/08 06:00
PHST- 2019/03/15 00:00 [received]
PHST- 2019/07/26 00:00 [revised]
PHST- 2019/08/19 00:00 [accepted]
PHST- 2019/09/08 06:00 [pubmed]
PHST- 2020/05/19 06:00 [medline]
PHST- 2019/09/08 06:00 [entrez]
AID - S1096-6374(19)30038-3 [pii]
AID - 10.1016/j.ghir.2019.08.001 [doi]
PST - ppublish
SO  - Growth Horm IGF Res. 2019 Oct-Dec;48-49:16-28. doi: 10.1016/j.ghir.2019.08.001. 
      Epub 2019 Aug 21.